Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilars Among 100+ Guidances FDA Plans For 2016

This article was originally published in Scrip

Executive Summary

After missing its goal last year to issue much-anticipated guidances for biosimilar makers about interchangeability, labeling and statistical approaches to analytical similarity, the FDA said it's going to give it another go and try to get them done before the end of 2016, although the agency didn't provide a specific timeline.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register